Manuel Wallbach1, Luca-Yves Lehnig2, Hans-Joachim Helms3, Charlotte Schroer4, Gerhard A Müller2, Rolf Wachter4, Michael J Koziolek2. 1. Department of Nephrology and Rheumatology, Georg-August-University Göttingen, Robert - Koch - Str. 40, 37075, Göttingen, Germany. manuel.wallbach@med.uni-goettingen.de. 2. Department of Nephrology and Rheumatology, Georg-August-University Göttingen, Robert - Koch - Str. 40, 37075, Göttingen, Germany. 3. Department of Medical Statistics, Georg-August-University Göttingen, Göttingen, Germany. 4. Department of Cardiology and Pneumology, Georg-August-University Göttingen, Göttingen, Germany.
Abstract
AIMS: Sympathetic overactivity is one critical factor associated with the development of arterial hypertension, impaired insulin secretion and resistance. Some antihypertensives exert beneficial effects on glucose metabolism, whereas others lead to an impairment of metabolic state with consecutive weight gain. In resistant hypertension, baroreflex activation therapy (BAT) reduces arterial blood pressure (BP) by inhibition of the sympathetic nervous system. The objective of this study was to evaluate whether BAT influences metabolic state in patients with resistant hypertension. METHODS: Thirty patients with resistant hypertension (10 with known diabetes mellitus) were prospectively included into this study. Blood pressure, BMI, weight, fasting glucose, insulin, C-peptide, hemoglobin A1c, HOMA-IR, HOMA-β, ISQuickI, and glucose levels during oral glucose tolerance test were measured at baseline and 6 months after BAT activation. RESULTS: Fasting glucose was significantly reduced after 6 months of BAT, whereas mean 2-h glucose levels during oral glucose tolerance test, fasting insulin levels, C-peptide levels, hemoglobin A1c, HOMA-IR, HOMA-β, ISQuickI, weight, and BMI remained unchanged. CONCLUSION: Despite improvement in fasting glucose, BAT exerts neither sustained additional beneficial effects nor an impairment of metabolic state. Thus, chronic BAT might be an effective interventional method to reduce BP without metabolic disadvantages.
AIMS: Sympathetic overactivity is one critical factor associated with the development of arterial hypertension, impaired insulin secretion and resistance. Some antihypertensives exert beneficial effects on glucose metabolism, whereas others lead to an impairment of metabolic state with consecutive weight gain. In resistant hypertension, baroreflex activation therapy (BAT) reduces arterial blood pressure (BP) by inhibition of the sympathetic nervous system. The objective of this study was to evaluate whether BAT influences metabolic state in patients with resistant hypertension. METHODS: Thirty patients with resistant hypertension (10 with known diabetes mellitus) were prospectively included into this study. Blood pressure, BMI, weight, fasting glucose, insulin, C-peptide, hemoglobin A1c, HOMA-IR, HOMA-β, ISQuickI, and glucose levels during oral glucose tolerance test were measured at baseline and 6 months after BAT activation. RESULTS: Fasting glucose was significantly reduced after 6 months of BAT, whereas mean 2-h glucose levels during oral glucose tolerance test, fasting insulin levels, C-peptide levels, hemoglobin A1c, HOMA-IR, HOMA-β, ISQuickI, weight, and BMI remained unchanged. CONCLUSION: Despite improvement in fasting glucose, BAT exerts neither sustained additional beneficial effects nor an impairment of metabolic state. Thus, chronic BAT might be an effective interventional method to reduce BP without metabolic disadvantages.
Authors: Mark Lipphardt; Michael J Koziolek; Luca-Yves Lehnig; Ann-Kathrin Schäfer; Gerhard A Müller; Stephan Lüders; Manuel Wallbach Journal: Clin Res Cardiol Date: 2019-04-06 Impact factor: 5.460
Authors: M Koziolek; J Beige; M Wallbach; D Zenker; G Henning; M Halbach; N Mader; F Mahfoud; G Schlieper; V Schwenger; M Hausberg; J Börgel; M Lodde; M van der Giet; J Müller-Ehmsen; J Passauer; S Parmentier; S Lüders; B K Krämer; S Büttner; F Limbourg; J Jordan; O Vonend; H-G Predel; H Reuter Journal: Internist (Berl) Date: 2017-10 Impact factor: 0.743
Authors: Revathy Carnagarin; Kearney Tan; Leon Adams; Vance B Matthews; Marcio G Kiuchi; Leslie Marisol Lugo Gavidia; Gavin W Lambert; Elisabeth A Lambert; Lakshini Y Herat; Markus P Schlaich Journal: Int J Mol Sci Date: 2021-04-19 Impact factor: 5.923